Postdoctoral Fellowships in translational research at Harvard Medical School
Postdoctoral Fellowships funded by NIH are available in Drs. Kun Ping Lu and Xiao Zhen Zhou laboratories at Harvard Medical School to study the role of the unique proline isomerase Pin1 in the development and treatment of Alzheimer’s disease, brain injury, cancer, autoimmune disorders and infection, focusing on Pin1 inhibitors and cis and trans-specific antibodies in disease mechanisms, diagnosis and treatment.
Kondo, A., Shahpasand, K., …, Zhou, X. Z. and Lu, K. P. 2015, Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 523: 431-436. (Research article)
Nakamura, K., Greenwood, A., Binder, L., Bigio, E. H., Denial, S. J., Nicholson, L., Zhou, X. Z. and Lu, K. P. 2012. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer’s disease. Cell 149: 232-244.
Lu, K. P., Kondo, A., Albayram, O., Herbert, M., Liu, H., and Zhou, X. Z. 2016. Therapeutic potential of antibody against precursor of tauopathy cis P-tau in early treatment and prevention of Alzheimer’s disease and brain injury. JAMA Neurol 73:1356-1362.
Wei, S., Kats, L., …, Pandolfi, P. P., Zhou, X. Z. and Lu, K. P. 2015, Active Pin1 as a target of ATRA in acute promyelocytic leukemia and breast cancer. Nature Med 21: 457-466.
Zhou, X. Z. and Lu, K. P. 2016, The isomerase Pin1 controls numerous cancer-driving pathways and is a unique drug target. Nat. Rev. Cancer 16: 463-478.
Albayram, O., Kondo, A., …, Lu, K. P. and Zhou, X. Z. 2017. Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae. Nature Commun 8:1000.
Kozono, S., Lin, Y. M., …, Lu, K. P. and Zhou, X. Z. 2018. Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun 9: 3069. PMCID: PMC6085299